The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

Bayer announced the FDA approved finerenone, a nonsteroidal selective mineralocorticoid receptor antagonist, for the ...

Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...

Finerenone gained FDA approval for heart failure treatment, showcasing significant benefits in reducing cardiovascular events ...

The going has been good for the German pharmaceutical giant Bayer BAYRY this year. Shares have surged 62.9% year to date ...

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

Finerenone may lower risks for kidney and cardiovascular events for adults with chronic kidney disease and type 2 diabetes, ...

The US Food and Drug Administration has approved the use of finerenone (Kerendia) in heart failure (HF) patients with mildly ...

Berlin: Bayer has received approval from the U.S. Food and Drug Administration (FDA) for finerenone (Kerendia), a ...

Real-world data suggest that finerenone is both effective and safe for patients with non-diabetic chronic kidney disease (CKD), although larger prospective studies are necessary to validate ...